Lancet:32种常见抗精神分裂药物的疗效及不良事件差异研究

2019-09-13 MedSci MedSci原创

32种常见口服抗精神病药物之间有一定的疗效差异,副作用的差异更为明显

精神分裂症是全世界最难以治疗的精神疾病之一。近日研究人员对32种口服抗精神分裂症药物的疗效进行了比较。

本次研究为系统综述及荟萃分析,涉及32种药物的安慰剂对照以及头碰头研究,数据截止时间为2019年1月8日。研究的主要终点为采用标准化评分表来衡量整体症状变化。

402项研究,包含53463名参与者,影响大小估计显示,所有抗精神病药物均比安慰剂可减少总体症状,标准平均差异从氯氮平的-0.89到左美丙嗪的-0.03不等。与安慰剂相比,减少阳性症状标准化的平均差异,从氨磺必利的-0.69到格列哌唑的-0.17。减少阴性症状标准化的平均差异,从氯氮平的-0.62到氟哌噻吨的-0.10。对于抑郁症状,从舒必利的-0.90到氟哌噻吨的-0.04。相比于安慰剂,全因停药风险,从氯哌噻吨的的0.52到哌莫齐特的1.15。对于服用镇静剂导致的休眠状态,从哌莫齐特的0.92到珠氯噻醇的10.20。对于抗帕金森样作用,从氯氮平的0.46到哌莫齐特的6.14。相比于安慰剂,体重增加不良事件从齐拉西酮的-0.16kg到苯噻庚乙胺的3.21kg。催乳素升高不良事件,从氯氮平的-77.05 ng/mL到帕潘立酮的48.51 ng/mL。QTC延长不良事件,从卢拉西酮的-2.21 ms到施立碟的23.90ms。

研究发现,32种常见口服抗精神病药物之间有一定的疗效差异,副作用的差异更为明显。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830251, encodeId=ebcc18302516a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 17 18:13:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373056, encodeId=482d3e30560c, content=棒!好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/20/8c11a0f1a795803ef50c306c573ddab0.jpg, createdBy=bd1b5191113, createdName=暖冬木吉他er, createdTime=Sun Sep 22 17:26:31 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404118, encodeId=ce8b1404118ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Sep 15 01:13:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032281, encodeId=9aa1103228152, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 13 13:13:00 CST 2019, time=2019-09-13, status=1, ipAttribution=)]
    2020-06-17 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830251, encodeId=ebcc18302516a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 17 18:13:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373056, encodeId=482d3e30560c, content=棒!好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/20/8c11a0f1a795803ef50c306c573ddab0.jpg, createdBy=bd1b5191113, createdName=暖冬木吉他er, createdTime=Sun Sep 22 17:26:31 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404118, encodeId=ce8b1404118ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Sep 15 01:13:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032281, encodeId=9aa1103228152, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 13 13:13:00 CST 2019, time=2019-09-13, status=1, ipAttribution=)]
    2019-09-22 暖冬木吉他er

    棒!好!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1830251, encodeId=ebcc18302516a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 17 18:13:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373056, encodeId=482d3e30560c, content=棒!好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/20/8c11a0f1a795803ef50c306c573ddab0.jpg, createdBy=bd1b5191113, createdName=暖冬木吉他er, createdTime=Sun Sep 22 17:26:31 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404118, encodeId=ce8b1404118ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Sep 15 01:13:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032281, encodeId=9aa1103228152, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 13 13:13:00 CST 2019, time=2019-09-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830251, encodeId=ebcc18302516a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jun 17 18:13:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373056, encodeId=482d3e30560c, content=棒!好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/20/8c11a0f1a795803ef50c306c573ddab0.jpg, createdBy=bd1b5191113, createdName=暖冬木吉他er, createdTime=Sun Sep 22 17:26:31 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404118, encodeId=ce8b1404118ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Sep 15 01:13:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032281, encodeId=9aa1103228152, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Sep 13 13:13:00 CST 2019, time=2019-09-13, status=1, ipAttribution=)]
    2019-09-13 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

2019 IPS临床实践指南:儿童和青少年精神分裂的管理

2019年1月,印度精神病学学会(IPS)发布了儿童和青少年精神分裂的管理指南,指南主要提供了精神分裂患者的评估和管理框架。

Neuron:自闭症或精神分裂,可能是大脑连接不足所致

乔治华盛顿大学(GW)神经科学研究所的研究人员最近的一项研究表明,大脑中连接不足或连接太少或是自闭症或精神分裂症等脑部疾病的发病原因。

JAMA Psychiatry:科学家发现精神分裂相关基因位点

复旦大学类脑智能科学与技术研究院冯建峰团队对来自英美等6个国家、20余所研究机构超过1万例影像遗传学数据进行计算分析,通过全脑全基因组范围的“广泛搜索”,发现与青春期大脑壳核体积相关的基因位点同时也是精神分裂症的风险位点。该成果近日发表于《美国医学会杂志—精神病学卷》。

CELL:遗传性精神分裂症认知功能障碍的长期改善

尽管致敏过程发生得更早,但精神分裂症在年轻的成年期被诊断出来,这表明它可能涉及在易感个体的晚期大脑发育期间的病理转变。

FDA批准PERSERIS(利培酮)延长释放悬浮液治疗成人精神分裂症

Indivior PLC近日宣布,美国食品和药物管理局(FDA)批准了PERSERI延长释放悬浮液(第一款每月一次的利培酮的皮下长效注射剂),用于治疗成人精神分裂症。在第一次注射PERSERIS后,患者在不使用任何补充口服利培酮的情况下即可达到临床改善水平。

Nat Neurosc:中外合作研究揭示精神疾病发生调控机制

近日,中国科学院动物研究所、美国埃默里大学医学院、中国科学院干细胞与再生医学创新研究院、中国科学院大学、美国圣裘德儿童研究医院,东南大学等机构合作,首次提供了miR-137缺失导致精神疾病的在体实验证据,进一步揭示miR-137缺失类的精神疾病的分子调控机制。